Endonovo Therapeutics (Endonovo Therapeutics) Total Assets : $0.64 Mil (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Endonovo Therapeutics Total Assets?

Endonovo Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $0.64 Mil.

During the past 12 months, Endonovo Therapeutics's average Total Assets Growth Rate was -50.40% per year. During the past 3 years, the average Total Assets Growth Rate was -37.40% per year. During the past 5 years, the average Total Assets Growth Rate was -29.30% per year. During the past 10 years, the average Total Assets Growth Rate was 35.70% per year.

During the past 13 years, Endonovo Therapeutics's highest 3-Year average Total Assets Growth Rate was 364.90%. The lowest was -64.30%. And the median was -16.90%.

Total Assets is connected with ROA %. Endonovo Therapeutics's annualized ROA % for the quarter that ended in Dec. 2023 was -881.98%. Total Assets is also linked to Revenue through Asset Turnover. Endonovo Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 was 0.01.

Endonovo Therapeutics Total Assets Historical Data

The historical data trend for Endonovo Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endonovo Therapeutics Total Assets Chart

Endonovo Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

3.28

2.61

2.01

1.28

0.64

Endonovo Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Assets	Get a 7-Day Free Trial															1.28	1.20	1.02	0.82	0.64

Endonovo Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Endonovo Therapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	-24.108	+	24.746
	=	0.64

Endonovo Therapeutics's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2023 )	+	Total Liabilities (Q: Dec. 2023 )
	=	-24.108	+	24.746
	=	0.64

Endonovo Therapeutics (OTCPK:ENDV) Total Assets Explanation

Total Assets is connected with ROA %.

Endonovo Therapeutics's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %	=	Net Income (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	-6.412	/	( (0.816	+	0.638)	/ 2 )
	=	-6.412	/	0.727
	=	-881.98 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Endonovo Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 is

	Asset Turnover
=	Revenue (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
=	0.006	/	( (0.816	+	0.638)	/ 2 )
=	0.006	/	0.727
=	0.01

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Endonovo Therapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of Endonovo Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Endonovo Therapeutics (Endonovo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Endonovo Therapeutics Inc (OTCPK:ENDV) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

6320 Canoga Avenue, 15th Floor, Woodland Hills, CA, USA, 91367

Website

https://www.endonovo.com

Endonovo Therapeutics Inc is an us-based biotechnology company that focuses on the business of biomedical research and development, particularly in regenerative medicine, which has included the development of its proprietary square waveform device. It is engaged in developing the Immunotronics platform which is non-implantable, a non-invasive medical device to target inflammatory conditions in vital organs; and the Cytotronics platform which uses Time-Varying Electromagnetic Fields technology for the creation of cell-based therapies. The company generates its revenue through its technology licensing and commercialization activities.

Executives

Alan Brian Collier	director, 10 percent owner, officer: CEO	6320 CANOGA AVENUE, 15TH FLOOR, WOODLAND HILLS CA 91367
Michael Scott Mann	10 percent owner, officer: President	6320 CANOGA AVENUE, WOODLAND HILLS CA 91367